Meet The Team
Lily Yang
Dr. Yang, MD, PhD, is the President of MIGRA Therapeutics, LLC. She is also Professor of Surgery and Radiology in the Departments of Surgery and Radiology and Imaging Sciences, and Nancy Panoz Chair of Surgery in Cancer Research. Dr. Yang has expertise in tumor biology, targeted cancer therapy, animal tumor models, and the development of multifunctional nanoparticles for targeted and image-guided therapy.
Lei Zhu
Dr. Lei Zhu, Ph.D. is the Co-Founder and Chief Operating Officer of MIGRA-Therapeutics, LLC. He is also an assistant professor of Surgical Oncology in the Departments of Surgery at Emory University. Dr. Zhu has been working on recombination protein engineering and purification, protein structure and function, biochemistry, and molecular biology, nanoparticle production, hyaluronic acid-based nanoparticle drug carrier development, and in vivo animal imaging and therapy studies for over ten years. His translational studies have been supported by NIH Small Business Innovation Research (SBIR) phase I and SBIR phase II grants.
Yunfeng Lin
Dr. Yunfeng Lin is a Research Scientist at MIGRA-Therapeutics since April 2023. He obtained his Ph.D. from Jackson State University in 2015 and received his postdoc training in cell biology at University of North Carolina from 2015-2022. He has rich experience in nanomaterial development and drug delivery. His current research project will be focused on the translational development of polymeric nanoparticle for drug delivery. He is also in charge of developing the standard Operation Protocols (SOPs) for the production of these nanomaterials a at MIGRA-Therapeutics.
Yuqi Wu
Dr. Wu is a Research scientist at MIGRA Therapeutics, LLC, who recently earned his Ph.D. from the Georgia Institute of Technology in 2023. Following his graduation, Dr. Wu promptly joined the MIGRA Therapeutics team, focusing on the development of tumor-targeting and tumor-stroma-penetrating agents utilizing various expression systems. He provides his expertise in protein expression and purification optimizing in MIGRA-NP01 production. Dr. Wu will lead the establishment of SOP for tumor-targeting ligand production, ensuring the consistency and quality of our research efforts.
Tianhu Sun
Dr. Tianhu Sun is a Research Scientist at MIGRA-Therapeutics since March 2023. He obtained his Ph.D. from Nanjing University in 2015 and received his postdoc training in protein-protein interactions at Cornell University from 2016-2022. Dr. Sun has rich experience in molecular biology and protein chemistry. His current research project will be focused on the translational development of gene-based or recombinant protein-based novel cancer therapeutic agents. He is also in charge of developing the standard Operation Protocols (SOPs) for the production of these vector and recombinant proteins at MIGRA-Therapeutics.